Recommendation from Finance and Healthcare Sector

The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations

Capital India Finance Ltd
CMP - ₹38.56
BSE CODE 530879
Volume 35,857
Face Value ₹2
Target ₹42 - ₹44
Stoploss ₹36 (CLS)

The company is a technology-driven, India-focused SME finance platform offering tailored financial solutions to small and medium enterprises. The company provides a diverse suite of offerings including SME secured loans, supply chain finance, equipment finance, home loans, loans against property. In FY24-25, the company surpassed a significant milestone with AUM crossing ₹1,000 crore. Backed by a strong credit rating of “A” and a net NPA of just 0.98 per cent, it stands out for its prudent risk management and sound asset quality. Apart from its core business, the company also operates ‘RemitX’, which offers retail foreign exchange solutions, and ‘RapiPay Fintech Pvt Ltd’, one of the fastest-growing fintech firms in the Assisted Payments segment—further diversifying its presence in the financial services ecosystem. The company’s shareholder base includes reputed names such as Dharampal Satyapal Ltd, RJ Corp Ltd, and DLF Utilities Ltd—highlighting strong institutional confidence. Hence, we recommend a BUY.

GlaxoSmithKline Pharmaceuticals Ltd
CMP - ₹3,118.75
BSE CODE 500660
Volume 45,522
Face Value ₹10
Target ₹3,368 - ₹3,440
Stoploss ₹2,900 (CLS)

The company focuses on therapeutic areas like respiratory, anti-infectives, vaccines, and dermatology. The company continues to focus on innovationled growth, backed by its global R&D capabilities and strong domestic distribution network. With steady growth prospects and a renewed product pipeline, it remains a stable long-term investment candidate in the healthcare space. Reflecting its strong financial performance, the company reported a notable 9 per cent rise in revenue, growing from ₹3,454 crore in FY24 to ₹3,749 crore in FY25. Net profit witnessed a robust year-on-year jump of over 57 per cent, reaching ₹928 crore—highlighting operational efficiency and improved profitability. The company’s board has recommended a final dividend of ₹42 per equity share of face value ₹10 each for FY25. The stock has demonstrated strong resilience, delivering a robust 40 return year-to-date despite broader market weakness. With the ongoing rally supported by solid investor confidence and further upside potential, we recommend a BUY.

(Closing price as of May 27, 2025)